Ideas about Implementation of Microbial Environmental Monitoring Program for Non Sterile Forms
Abstract:This article establishes a rationale to justify the level and extension of Environmental Monitoring to be applied at non-sterile pharma facilities based on the risk compound by factors such as location and product susceptibility to microbial contamination.
The author, Marcelle Cortezia, has ten years of experience with major pharmaceutical companies and is at present a Quality Manager with Dentsply.
Click here to download the file
Trending Compliance Trainings
Understanding and Implementing USP <1058>: Analytical Instrument Qualification
By - Dr. Ludwig Huber
On Demand Access Anytime
By - Dr. Ludwig Huber
On Demand Access Anytime
Avoiding FDA observations: Do's and Don'ts during Laboratory Inspections
By - Kim Huynh-Ba
On Demand Access Anytime
By - Kim Huynh-Ba
On Demand Access Anytime
Addressing Non-Conformances using Root Cause Analysis (RCA)
By - Michael Brodsky
On Demand Access Anytime
By - Michael Brodsky
On Demand Access Anytime
How Medicare's Market-Based Payment System Is Upending the U.S. Clinical Laboratory Market
By - Dennis Weissman
On Demand Access Anytime
By - Dennis Weissman
On Demand Access Anytime
The Use of Monitoring and Statistics to Prevent Non-Compliance in the Laboratory
By - John Fetzer
On Demand Access Anytime
By - John Fetzer
On Demand Access Anytime
Where FDA Is Heading in Regulating Laboratory-Developed Tests
By - Dennis Weissman
On Demand Access Anytime
By - Dennis Weissman
On Demand Access Anytime
Data Integrity in the Pharmaceutical Laboratory: Practical Steps to Identify and Avoid Data Integrity Issues
By - Gregory Martin
On Demand Access Anytime
By - Gregory Martin
On Demand Access Anytime
You Recently Viewed
